| Title |
Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
|
|---|---|
| Published in |
Open Access Journal of Clinical Trials, February 2018
|
| DOI | 10.2147/oajct.s155706 |
| Authors |
Tatsunori Shimoi, Akihiko Shimomura, Tadahiko Shien, Yukari Uemura, Hiroaki Kato, Masahiro Kitada, Tatsuya Toyama, Tomohiko Aihara, Hirofumi Mukai |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 2 | 13% |
| Researcher | 2 | 13% |
| Student > Bachelor | 2 | 13% |
| Librarian | 1 | 6% |
| Lecturer | 1 | 6% |
| Other | 2 | 13% |
| Unknown | 6 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 50% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Psychology | 1 | 6% |
| Engineering | 1 | 6% |
| Unknown | 5 | 31% |